You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023176012
Dec 20237908
Jan 20247006
Feb 20246005
Mar 20244003
Apr 20243802
May 20243401
Jun 20242203
Jul 20242604
Aug 20242203
Sep 20243806
Oct 20243804
Nov 20242603
Dec 20241801
Jan 20252207
Feb 2025205
Mar 2025004
Apr 2025001
May 2025004
Jun 2025002
Total711084